Methylenetetrahydrofolate reductase gene polymorphism in type 1 diabetes mellitus: Relationship to microvascular complications  by AboElAsrar, Mohammed A et al.
The Egyptian Journal of Medical Human Genetics (2012) 13, 139–145Ain Shams University
The Egyptian Journal of Medical Human Genetics
www.ejmhg.eg.net
www.sciencedirect.comORIGINAL ARTICLEMethylenetetrahydrofolate reductase gene polymorphism
in type 1 diabetes mellitus: Relationship to microvascular
complicationsMohammed A AboElAsrar a,*, Ahmed Al-saeed Hamed a, Nejat Akar b,
Yonca Egin b, Mai Mohamed Mahmoud Saied aa Department of Pediatrics, Faculty of Medicine, Ain Shams University, Cairo, Egypt
b Pediatric Molecular Genetics Department, Ankara University, TurkeyReceived 15 December 2011; accepted 10 January 2012
Available online 5 May 2012*
Eg
E-
A
11
El
Pe
htKEYWORDS
Methylenetetrahydrofolate
reductase gene
polymorphism;
Microvascular
complications;
Type 1 diabetes;
MicroalbuminuriaCorresponding author. Add
ypt. Tel.: +20 224177712; f
mail address: mohamedab
srar).
10-8630  2012 Ain Shams
sevier B.V. All rights reserve
er review under responsibilit
tp://dx.doi.org/10.1016/j.ejmh
Production and hress: Mee
ax: +20
oelasrar2
Universit
d.
y of Ain
g.2012.0
osting by EAbstract In patients with type-I diabetes mellitus folate deﬁciency is associated with endothelial
dysfunction. So, polymorphism in genes involved in folate metabolism may have a role in vascular
disease. This study was designed to evaluate the relationship between methylenetetrahydrofolate
reductase (MTHFR) gene polymorphism and microvascular complications in adolescents with type
I diabetes mellitus.
A total of 99 patients with disease duration of more than 5 years aged 11–18 years participated in
the study. History taking, physical, neurological and fundus examinations were performed. Labo-
ratory investigations included mean glycated hemoglobin in the last year, urinary albumin excre-
tion, serum creatinine, nerve conduction velocity and MTHFR genotype determination.
Results revealed that 54 (54.5%) of our patients had normal MTHFR genotype (C/C subgroup),
36 (36.4%) had heterozygous MTHFR gene polymorphism (C/T subgroup) and 9 (9.1%) had
homozygous MTHFR gene polymorphism (T/T subgroup). No signiﬁcant difference was found
between the three studied groups as regards age, disease duration or glycemic control. When testingt El-Atar, Benha, Kalyobya,
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140 M.A AboElAsrar et al.for microalbuminuria, the T/T subgroup showed a signiﬁcantly higher number of patients with
microalbuminuria when compared with C/C and C/T subgroups.
Regarding fundus changes, the C/C subgroup showed a signiﬁcantly lower number of patients
with fundus changes when compared with C/T and T/T subgroups .On the other hand the T/T
subgroup showed a signiﬁcantly higher number of patients with fundus changes when compared
with the C/T subgroup.
For nerve conduction abnormalities, the T/T subgroup showed a signiﬁcantly higher number of
patients with nerve conduction abnormalities when compared with C/C and C/T subgroups.
Multivariate forward stepwise logistic regression analysis for determination of independent risk
factors that best predicts the occurrence of microalbuminuria, fundus changes and nerve conduc-
tion abnormalities revealed MTHFR gene polymorphism to be the most important variable.
MTHFR gene polymorphism (T/T) subtype is an important risk factor for the development of
micro-vascular complications in patients with type I diabetes mellitus.
 2012 Ain Shams University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Type 1 diabetes mellitus (T1DM) is an autoimmune disorder
resulting in loss of pancreatic insulin-producing-cells that pre-
sents in childhood or early adulthood, along with an increased
risk of complications including retinopathy, nephropathy, neu-
ropathy, and cardiovascular events [1].
The risk of developing micro-vascular complications is re-
lated mainly to the duration of diabetes and the degree of gly-
cemic control achieved over time (i.e., HbA1c 7.0% or less).
Genetic factors may also inﬂuence the risk of complications.
These complications are mainly renal micro-vascular compli-
cation (microalbuminuria or diabetic nephropathy), retinopa-
thy and neuropathy (peripheral or autonomic) [2].
5, 10-methylenetetrahydrofolate reductase is a key enzyme
in folic acid metabolism. Folic acid has recently gained a great
deal of attention as a biologically important molecule. Methyl-
enetetrahydrofolate reductase is the enzyme responsible for
reduction of methylenetetrahydrofolate, to methyltetrahydro-
folate, which is essential for homocysteine remethylation to
methionine. In the absence, deﬁciency or decreased action of
this enzyme homocysteine will not be remethylated to methio-
nine and leads to elevation of its serum level [3,4].
Elevated homocysteine is a known risk factor for vascular
disease. So the polymorphism in methylenetetrahydrofolate
reductase may have detrimental consequences [5].
In patients with type-I diabetes mellitus folate deﬁciency is
associated with endothelial dysfunction and folate supplementa-
tion improves endothelial functions in these patients. The familial
clustering of nephropathy and retinopathy found in diabetes
control and complications trial supports a contribution of genetic
factors in their development. So, polymorphism in genes involved
in folate metabolism may have a role in vascular disease [5].
This study was designed primarily to investigate the
association between methylenetetrahydrofolate reductase gene
[MTHFR C677T] polymorphism and microvascular complica-
tions in patients with type-I diabetes mellitus.
2. Subjects and methods
2.1. Subjects
The present study included 99 type 1 diabetic patients with a
disease duration of more than 5 years recruited from theregular attendants of the Diabetes Specialized Clinic, Chil-
dren’s Hospital, Ain Shams University over a 10 month period
(from February to November 2010). The patients are regular
attendees at the Clinic which cares for more than 1500 chil-
dren, adolescents, and young adults with T1DM.
The patients included are those using human insulin in a dose
ranging from0.5 to 2 IU/kg/daywith amean of 1.12 ± 0.40 IU/
kg/day.All participants were on intensive insulin therapy. Sixty-
eight patients were on pre-prandial injections of short-acting
insulin plus intermediate acting insulin (isophane NPH insulin)
and 31 patients were on long acting insulin analog (insulin
glargine – Aventis Pharma) at bedtime plus pre-prandial short
acting insulin analog.
The study has been approved by the Ethics Committee of
Ain Shams University. Subjects participated in the study after
written information and informed consent from their parents.
2.2. Methods
All subjects underwent the following:
2.2.1. Detailed questionnaire
Complete history was taken including age of the patient at the
time of the study, age at the onset and duration of diabetes,
and symptoms suggesting diabetic complications.
2.2.2. Clinical assessment
Physical examination included full neurological examination
to detect evidence of peripheral neuropathy. Diabetic neurop-
athy was diagnosed in the presence of typical neuropathic
symptoms and positive ﬁndings related to neuropathy in neu-
rological examination. Diabetic retinopathy (DR) was diag-
nosed by doing a complete ocular examination including
visual ﬁeld testing, slit-lamp biomicroscopy and indirect
ophthalmoscopy.
2.2.3. Biochemical investigations
Venous blood samples were obtained in the morning from all
patients after an overnight fast. A sample of 4 ml of blood was
drawn from peripheral veins under complete aseptic conditions
and divided among two tubes. One tube contained EDTA for
direct assay of HbA1c by high performance liquid chromatog-
raphy supplied by Bio-Rad Diagnostic Group. Horcules C.A.
Milano, Muchon, Paris (normal levels in our lab is less than
Table 1 Normal value of motor nerve conduction studies of median and posterior tibial nerves [7].
Nerve Active electrode Stimulation site Latency (ms) Amplitude Segment name Velocity m/s
Median nerve Abductor pollicis brevis Wrist–elbow <4.2 >4 (mV) Wrist–elbow >50
Posterior tibial nerve Abductor hallucis Ankle–knee <6 >3 (Uv) Ankle–knee >40
Table 2 Age and disease duration in all studied groups.
CC subgroup C/T subgroup T/T subgroup
Age (years) 14.02 ± 3.53 13.06 ± 4.39 14.56 ± 3.9
Disease
duration
(years)
6.94 ± 3.3 6.72 ± 3.83 9.44 ± 4.28
Methylenetetrahydrofolate reductase gene polymorphism in type 1 diabetes mellitus 1415.5 g%) and the other tube for MTHFR polymorphism
analysis.
Urinary albumin excretion was measured by immuno-turbi-
dimetric method. The kit used was from SERA-PAK (Bayer
Corporation, Bendict Ave, Tarry town, NY, USA). The result
was expressed as albumin to creatinine ratio (ACR) in urine
to avoid diurnal variation in albumin excretion. Urinary creat-
inine was estimated using Synchron Cx7 (Beckman Instruments
Inc., Brea., California, USA).
Patients with diabetic nephropathy were classiﬁed into two
groups: group 1 (84) normoalbuminuric patients (with urinary
albumin levels of <29 mg/g); group 2 (15) microalbuminuric
patients (with urinary albumin levels of 30–299 mg/g) in at
least 2 urine samples, 2 months apart.
2.2.4. Testing for neuropathy
2.2.4.1. Nerve conduction velocity (NCV). Motor nerve
conduction studies for both median and posterior tibial nerves
bilaterally were done by the Nicollet Viking Quest 4 Channel
apparatus a product of Viasys Healthcare Neurocare Group
USA [6].
Results were compared with the normal values shown in
Table 1.
2.2.5. Methylenetetrahydrofolate reductase gene polymorphism
analysis (MTHFR C677T)
For all cases the following were done:
2.2.5.1. DNA extraction. Genomic DNA was extracted using
QIAmpl DNA extraction kit (Ca 51104).
2.2.5.2. Polymerase chain reaction (PCR). Polymerase chain
reaction (PCR) was performed according to the method de-
scribed by Frosst et al. [8]. One microliter of genomic DNA
was ampliﬁed in a 50 lL reaction volume containing 50 mM
KCL, 10 mM Tris–HCL pH 8.3, 1.5 mM MCL2, 20 mM
dNTPs, 0.5 lM primers and one unit of Taq DNA polymerase
enzyme. PCR consisted of initial denaturation at 94 C for
150 s followed by 35 cycles at 94 C for 30 s, 57 C for 60 s
and 72 C for 120 s and a ﬁnal elongation step at 72 C for
3 min. PCR product of 198 bp was analyzed on 3% agarose
gel electrophoresis.
2.2.5.3. Enzyme digestion. Twenty microliters of PCR product
was mixed with 5 units of Hinf1 (promega, Madison) enzymeat 37 C overnight incubation. The substitution created a
Hinf1 recognition sequence that is digested into 175-bp and
23-bp.
2.3. Statistical analysis
Statistical analysis of the data was performed by using SPSS
15 software package under Windows XP operating system.
Categorical data parameters were presented in the form of
frequency and percentage and analyzed for group differences
by using Chi square test (v2 value) or Fisher exact test (X2
value) according to the nature of the data. Continuous data
parameters were analyzed for normality by using Shapiro–
Wilk and Kolmogorov–Smirnov tests. Central tendency of
the data was presented in the form of mean and/or median;
and measure of spread was presented as standard deviation,
range and/or percentile. Comparative analysis was performed
by using Student-t test (t value) or Mann–Whitney U test (z
value) for two independent samples according to the nature
of the data. Multivariate logistic regression analysis was used
for determination of best predictor models. Probability level
(P value) was assumed signiﬁcant if less than 0.05 and highly
signiﬁcant if P value was less than 0.01. P value was consid-
ered non-signiﬁcant if greater than or equal to 0.05. Graphic
presentation of data was done by using EXCEL 2007
software.
3. Results
Our results revealed that 54 (54.5%) of our patients had homo-
zygous MTHFR genotype (C/C subgroup), 36 (36.4%) had
heterozygous MTHFR gene polymorphism (C/T subgroup)
and 9 (9.1%) had homozygous MTHFR gene polymorphism
(T/T subgroup).
3.1. Age
No signiﬁcant difference was found between the three studied
subgroups as regards age for C/C versus C/T, C/C versus T/T
and C/T versus T/T, respectively (Table 2).
3.2. Disease duration
Regarding disease duration, no signiﬁcant difference was found
between the three studied subgroups for C/C versus C/T, C/C
versus T/T and C/T versus T/T, respectively (Table 2).
3.3. Glycemic control
As regards HbA1c no signiﬁcant difference was found when
the C/C subgroup was compared with C/T and with T/T
subgroups. On the other hand, the T/T subgroup showed
Table 3 Comparison between the three MTHFR subgroups
regarding HbA1c (in g%).
C/C C/T T/T
Mean ± SD 8.16 ± 1.71 7.74 ± 0.96 8.72 ± 0.91
Median 8.45 7.95 8.30
Range (5.10–11.70) (5.40–10.10) (8–10.50)
z value/t value P value Signiﬁcance
C/C versus C/T 1.516 0.129 NS
C/C versus T/T 0.659 0.510 NS
C/T versus T/T 3.072 0.002 S
NS = non signiﬁcant.
S = signiﬁcant.
142 M.A AboElAsrar et al.signiﬁcantly higher HbA1c when compared with the C/T
subgroup (Table 3).
3.4. Microalbuminuria
As regards microalbuminuria no signiﬁcant difference was
found when the C/C subgroup was compared with the C/T
subgroup. On the other hand, the T/T subgroup showed a sig-
niﬁcantly higher number (7 out of 9) of patients with microal-
buminuria when compared with the C/C subgroup (2 out of
54) and the C/T subgroup (6 out of 36) (Table 4).
3.5. Fundus changes
As regards fundus changes the C/C subgroup showed a signif-
icantly lower number (2 out of 54) of patients with fundus
changes when compared with C/T (7 out of 36) and T/T (8
out of 9) subgroups. On the other hand the T/T subgroupTable 4 Comparison between the three MTHFR subgroups regard
C/C (n= 54)
No.
Microalbuminuria ve 52
+ve 2
X2 value
C/C versus C/T 4.482
C/C versus T/T 34.568
C/T versus T/T 13.089
Fundus changes ve 52
+ve 2
X2 value
C/C versus C/T 5.947
C/C versus T/T 41.921
C/T versus T/T 15.625
Nerve conduction abnormalities ve 51
+ve 3
X2 value
C/C versus C/T 1.852
C/C versus T/T 30.133
C/T versus T/T 15.028
NS = non signiﬁcant.
S = signiﬁcant.showed a signiﬁcantly higher number of patients with fundus
changes when compared with the C/T subgroup (Table 4).
3.6. Nerve conduction abnormalities
As regards nerve conduction abnormalities non-signiﬁcant dif-
ference was found when the C/C subgroup was compared with
the C/T subgroup. On the other hand, the T/T subgroup
showed a signiﬁcantly higher number of patients (7 out of 9)
with nerve conduction abnormalities when compared with C/
C (3 out of 54) and C/T (5 out of 36) subgroups (Table 4).
3.7. Predictors of different microvascular complications
A set of risk factors including age, duration of diabetes,
HbA1c and MTHFR gene mutation was used to predict the
occurrence of different microvascular complications. Risk fac-
tors were analyzed by regression analysis either in single-vari-
able model, double-variable model, triple-variable model, or
quad-variable-model.
As a single-variable, it was found that MTHFR gene poly-
morphism was the best predictor of microalbuminuria, fundus
changes and NCV abnormalities with 89.9% of cases correctly
classiﬁed (Table 5). Sensitivity, speciﬁcity, positive and nega-
tive predictive values are shown in Tables 6, 8 and 10.
By using the double variable model, MTHFR gene
polymorphism and disease duration were the best predictors
for the occurrence of microalbuminuria and fundus changes
while MTHFR and age were the best predictors for the
occurrence of NCV abnormalities. Sensitivity, speciﬁcity, posi-
tive and negative predictive values are shown in (Tables 7, 9
and 11).ing different microvascular complications.
C/T (n= 36) T/T (n= 9)
% No. % No. %
96.3 30 83.3 2 11
3.7 6 16.7 7 77
P value Signiﬁcance
0.056 NS
<0.001 S
0.001 S
96.3 29 80.6 1 11.1
3.7 7 19.4 8 88.9
P value Signiﬁcance
0.027 S
<0.001 S
<0.001 S
94.4 31 86.1 2 11.1
5.6 5 13.9 7 77.8
P value Signiﬁcance
0.258 NS
<0.001 S
<0.001 S
Table 6 Percent of microalbuminuria cases correctly classi-
ﬁed based on model 1 of binary logistic regression analysis.
Microalbuminuria (model 1) Expected
Negative Positive
Observed Negative 82 (TN) 2 (FP)
Positive 8 (FN) 7 (TP)
Sensitivity 46.7%
Speciﬁcity 97.6%
PPV 77.8%
NPV 91.1%
Diagnostic accuracy 89.9%
TN (true negative), FN (false negative), TP (true positive), FP
(false positive).
T
a
b
le
5
M
u
lt
iv
a
ri
a
te
fo
rw
a
rd
st
ep
w
is
e
lo
g
is
ti
c
re
g
re
ss
io
n
a
n
a
ly
si
s
fo
r
d
et
er
m
in
a
ti
o
n
o
f
in
d
ep
en
d
en
t
ri
sk
fa
ct
o
rs
th
a
t
b
es
t
p
re
d
ic
t
th
e
o
cc
u
rr
en
ce
o
f
d
if
fe
re
n
t
m
ic
ro
v
a
sc
u
la
r
co
m
p
li
ca
ti
o
n
s.
V
a
ri
a
b
le
s
en
te
re
d
B
co
eﬃ
ci
en
t
O
m
n
ib
u
s
X
2
v
a
lu
e
P
v
a
lu
e
P
er
ce
n
t
co
rr
ec
tl
y
cl
a
ss
iﬁ
ed
M
ic
ro
a
lb
u
m
in
u
ri
a
F
u
n
d
u
s
ch
a
n
g
es
N
C
V
a
b
n
o
rm
a
li
ti
es
M
ic
ro
a
lb
u
m
in
u
ri
a
F
u
n
d
u
s
ch
a
n
g
es
N
C
V
a
b
n
o
rm
a
li
ti
es
M
ic
ro
a
lb
u
m
in
u
ri
a
F
u
n
d
u
s
ch
a
n
g
es
N
C
V
a
b
n
o
rm
a
li
ti
es
S
te
p
1
M
T
H
F
R
2
5
.1
3
2
3
1
.9
4
8
2
2
.4
9
6
<
0
.0
0
1
<
0
.0
0
1
<
0
.0
0
1
8
9
.9
%
M
T
H
F
R
[1
]
4
.5
1
1
5
.3
3
8
4
.0
8
6
M
T
H
F
R
[1
]
2
.8
6
2
3
.5
0
1
3
.0
7
7
S
te
p
2
D
u
ra
ti
o
n
0
.2
5
2
0
.2
2
9
0
.2
7
4
9
.3
9
6
7
.5
9
2
1
0
.6
8
2
0
.0
0
2
0
.0
0
6
0
.0
0
6
8
8
.9
%
M
T
H
F
R
M
T
H
F
R
[1
]
4
.5
7
1
5
.4
2
2
1
.5
7
2
M
T
H
F
R
[1
]
2
.6
9
3
3
.3
6
4
3
.3
5
9
V
a
ri
a
b
le
en
te
re
d
in
st
ep
1
:
M
T
H
F
R
(c
o
n
st
a
n
t
=
1
.2
5
3
).
V
a
ri
a
b
le
en
te
re
d
in
st
ep
2
:
D
u
ra
ti
o
n
(c
o
n
st
a
n
t
=
0
.8
5
1
)
fo
r
m
ic
ro
a
lb
u
m
in
u
ri
a
a
n
d
fu
n
d
u
s
ch
a
n
g
es
a
n
d
a
g
e
(c
o
n
st
a
n
t
=
2
.4
8
5
)
fo
r
N
C
V
a
b
n
o
rm
a
li
ti
es
.
Table 8 Percent of fundus change cases correctly classiﬁed
based on model 1 of binary logistic regression analysis.
Fundus changes (model 1) Expected
Negative Positive
Observed Negative 81 (TN) 1 (FP)
Positive 9 (FN) 8 (TP)
Sensitivity 47.1
Speciﬁcity 98.8%
PPV 88.9%
NPV 90.0%
Diagnostic accuracy 89.9%
TN (true negative), FN (false negative), TP (true positive), FP (false
positive).
Variable entered in step 1, MTHFR (constant = 2.079).
Variable entered in step 2, Duration (constant = 0.231).
Table 7 Percent of microalbuminuria cases correctly classiﬁed
based on model 2 of binary logistic regression analysis.
Microalbuminuria (model 2) Expected
Negative Positive
Observed Negative 82 (TN) 3 (FP)
Positive 7 (FN) 7 (TP)
Sensitivity 50.0
Speciﬁcity 96.5%
PPV 70.0%
NPV 92.1%
Diagnostic accuracy 89.9%
TN (true negative), FN (false negative), TP (true positive), FP (false
positive).
Methylenetetrahydrofolate reductase gene polymorphism in type 1 diabetes mellitus 1434. Discussion
Homozygosity of the mutation (TT genotype of HTHFR
gene) predisposes to signiﬁcantly elevated plasma homocyste-
ine levels [8,9]. Thus MTHFR C677T gene polymorphism
associated with increased plasma homocysteine levels may
present a genetic risk factor for microangiopathy [10].
Table 9 Percent of fundus change cases correctly classiﬁed
based on model 2 of binary logistic regression analysis.
Fundus changes (model 2) Expected
Negative Positive
Observed Negative 80 (TN) 2 (FP)
Positive 8 (FN) 9 (TP)
Sensitivity 52.9%
Speciﬁcity 97.6%
PPV 81.8%
NPV 90.9%
Diagnostic accuracy 89.9%
TN (true negative), FN (false negative), TP (true positive), FP (false
positive).
Table 10 Percent of nerve conduction velocity abnormalities
cases correctly classiﬁed based on model 1 of binary logistic
regression analysis.
Nerve conduction
velocity abnormalities
(model 1)
Expected
Negative Positive
Observed Negative 82 (TN) 2 (FP)
Positive 8 (FN) 7 (TP)
Sensitivity 46.7%
Speciﬁcity 97.6%
PPV 77.8%
NPV 91.1%
Diagnostic accuracy 89.9%
TN (true negative), FN (false negative), TP (true positive), FP (false
positive).
Table 11 Percent of nerve conduction velocity abnormalities
cases correctly classiﬁed based on model 2 of binary logistic
regression analysis.
Nerve conduction velocity
abnormalities (model 2)
Expected
Negative Positive
Observed Negative 81 (TN) 3 (FP)
Positive 8 (FN) 7 (TP)
Sensitivity 46.7%
Speciﬁcity 96.4%
PPV 70.0%
NPV 91.0%
Diagnostic accuracy 88.9%
TN (true negative), FN (false negative), TP (true positive), FP (false
positive).
TN (true negative), FN (false negative), TP (true positive), FP (false
positive).
144 M.A AboElAsrar et al.Microangiopathy is the basic pathogenetic event in the
occurrences of most diabetic complications like nephropathy,
neuropathy and retinopathy [11]. This study was designed to
investigate the association between MTHFR gene polymor-
phism and the occurrence of different microvascularcomplications in patients with type 1 DM. Ninety-nine dia-
betic patients were analyzed as regards MTHFR genotype,
54 (54.5%) patients were found to be of the (C/C) genotype,
36 (36.4%) of the (C/T) genotype and 9 (9.1%) of the (T/T)
genotype and all subgroups were well matched regarding age.
When we investigated microvascular complications as
microalbuminuria, fundus changes and nerve conduction
abnormalities in the 3 groups the following interesting results
were found. Out of nine patients with the TT genotype, 7
(77.8%) had microalbuminuria and 8 (88.9%) had fundus
changes and 7 (77.8%) had nerve conduction abnormalities
with signiﬁcant difference between this group and patients with
either the C/C or C/T genotype. Is this a true effect or may be
affected by other parameters? When we compared between
patients with (T/T) genotype and other groups as regards
age, disease duration and HBA1c, we found non signiﬁcant
difference which emphasize that the high occurrence of micro-
vascular complications was caused by the MTHFR gene poly-
morphism and not by other factors. The last conclusion was
emphasized by the multivariate stepwise logistic regression
analysis which demonstrated that MTHFR gene polymor-
phism was an independent risk factor for the occurrence of
microalbuminuria, fundus changes and nerve conduction
abnormalities. In the literature there are some conﬂicting data.
A large meta-analysis done by Zintzraras et al. [11] re-
viewed 15 studies about the relationship between MTHFR
gene polymorphism and the occurrence of diabetic nephropa-
thy. These studies involved 8 Caucasians, 5 East Asians, one
mixed population and one Arab. Eleven studies involved sub-
jects with type 2 diabetes and 4 with type 1 diabetes. The stud-
ies provided 1871 cases and 2150 controls. The main analysis
for the investigation was the association between the T/T geno-
type and diabetic nephropathy which revealed signiﬁcant het-
erogeneity. Also in subgroup analysis (Caucasians versus
East Asians) and (type 1 versus type 2 diabetes) signiﬁcant het-
erogeneity was detected. Overall the meta-analysis results indi-
cated that homozygosity in allele T (T/T genotype) was
associated with a 65% increased risk of diabetic nephropathy
compared with homozygosity in allele C (C/C genotype). This
meta-analysis although did not reach a conclusive ﬁnal result
may be supported by the accumulating evidence of the effect
of homocysteine on endothelial cells and blood vessels. In
the beginning Fryer et al. [12] documented increased tissue fac-
tor activity in patients with elevated homocysteine levels which
represented an independent risk factor for premature arterial
vascular disease. Following Fryer, Hofmann et al. [13] docu-
mented the adverse effect of homocysteine in patients with
IDDM mainly the occurrence of cardiovascular disease and
diabetic nephropathy.
Also Ragone [14] emphasized the adverse effect of elevated
homocysteine on blood vessels and ﬁnally Dinelyici et al., [15]
found patients with type 1 DM with hyperhomocysteinemia to
have a reduced glomerular ﬁltration rate when compared to
normohomocysteinemic diabetic patients.
After this important meta-analysis Wiltshire et al. [5] re-
ported that the C/C genotype had a protective effect against
the occurrence of microalbuminuria. Finally Ukinc et al. [16]
stated a signiﬁcant correlation between diabetic nephropathy
and T/T polymorphism.
The association between retinopathy in type 2 diabetes
(DR) and the C677T polymorphism in the MTHFR gene
has been investigated in several case–control studies. These
Methylenetetrahydrofolate reductase gene polymorphism in type 1 diabetes mellitus 145studies rendered contradictory results, some indicating that the
polymorphism is associated with the risk of developing DR
whereas others concluded there is no association. To shed light
on these inconclusive ﬁndings, a meta-analysis of all available
studies relating the C677T polymorphism to the risk of devel-
oping DR was conducted. Four out of ﬁve identiﬁed studies in-
cluded populations of East Asian descent, and suggested large
heterogeneity between studies (p= 0.08, 1(2)–52%) and mar-
ginal association between C677T transition and the risk of
developing DR random effects odds ratio (OR) = 1.39 [95%
CI (1.05 1.83)] [17].
After this meta-analysis was published Maedia et al. [18]
and Wiltshire et al.[5] found patients with (T/T) genotype to
have reduced survival free of retinopathy. On the other hand
Ukinc et al. [16] did not ﬁnd any association between diabetic
retinopathy and MTHFR gene polymorphism.
We found very scarce data about the association between
this polymorphism and the occurrence of neuropathy, Ukinc
et al. [16], denied any association.
Why these conﬂicts and contradictory results?
First these studies were done on different ethnic groups and
our study may be one of the very few – if any studies were done
on Arabs and the ﬁrst study to be done in Egypt.
Second many studies were done on adults with type 2 DM
which may be totally different from the pediatric population
with type 1 diabetes.
Finally many results especially negative ones may be
unpublished or published in local journals which may add to
the conﬂict.
At the end our study demonstrated a strong association be-
tween MTHFR gene polymorphism (T/T genotype) and the
occurrence of all microvascular complications (nephropathy,
retinopathy and neuropathy) in patients with type 1 diabetes
mellitus in Egypt.
The authors declare that there is no conﬂict of interest.
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